Roche Pays $700M Upfront in $2.3B Nurix Deal
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Roche announces a $2.3 billion partnership with Nurix Therapeutics to develop a pill targeting blood cancers, multiple sclerosis and hives.
- Roche commits $700 million upfront for Nurix’s late‑phase BTK degrader, positioning the deal against Eli Lilly’s oncology pipeline.
- NRIX shares surge on Monday, becoming one of the day’s biggest stock movers.
Why it matters: Roche gains a late‑stage BTK degrader to bolster its oncology pipeline and pressure Lilly, while Nurix secures $700 million and a $2.3 billion partnership that lifts its valuation and stock price.
Ask SkimNews
